Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus Nab-Paclitaxel for MIBC
NCT05328336Phase 2Unknown
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Nov 2021
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in muscle-invasive bladder cancer (MIBC), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: Complete Response Rate at 12 weeks. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT05328336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05328336.